We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Antihypertensive Agents Reduce Heart Biomarkers Levels

By LabMedica International staff writers
Posted on 02 Jan 2018
Print article
Image: The Troponin T hs assay kit improves the detection and exclusion of myocardial injury in the early stages (Photo courtesy of Roche Diagnostics).
Image: The Troponin T hs assay kit improves the detection and exclusion of myocardial injury in the early stages (Photo courtesy of Roche Diagnostics).
High blood pressure (BP) is associated with an increased rate of cardiovascular events and mortality. Cardiovascular biomarkers are able to predict long-term risk in the general population, particularly in diseased cohorts.

Two different antihypertensive regimens had the effect of lowering blood pressure levels in patients while reducing both cardiac troponin levels measured by a high-sensitivity assay (hs-cTn) and B-type natriuretic peptide (BNP) concentrations.

Scientists at University Heart Center Hamburg (Hamburg, Germany) randomized into two cohorts of hypertensive patients at one healthcare center. In one group, 251 individuals received 80 mg telmisartan and 5 mg amlodipine, while in the other, 230 received 40 mg olmesartan and 12.5 mg hydrochlorothiazide. Patients prior to randomization and after six months had measurements of their blood pressure, hs-cTn I and T, BNP, and N-terminal-pro-BNP (NT-proBNP).

Various assays from Roche (Basel, Switzerland) and Abbott Laboratories (Abbott Park, IL, USA) were used to measure the cardiovascular biomarkers. The team reported that hs-cTnI concentrations declined markedly in both study groups and in the overall population dropped from 4.6 ng/L to 4.2 ng/L. In a subgroup analysis, the investigators discovered that male patients experienced a much higher reduction in hs-cTnI concentrations than their female counterparts. By comparison, hs-cTnT’s measurability was just 26.2% in the overall study population. Concentrations for this biomarker did not change after the intervention. BNP and NT-proBNP concentrations also were reduced after six months: from 15.0 ng/L to 12.4 ng/L and from 64.8 ng/L to 53.3 ng/L, respectively.

The authors concluded that they had determined that reducing blood pressure in patients led to a reduction in hs-cTnI, BNP, and NT-proBNP concentrations after half a year’s treatment with antihypertensive therapies. This effect was stronger when the combination of an angiotensin-receptor blocker with a calcium-channel blocker was used as compared to an angiotensin-receptor blocker and a diuretic. The study was published in the December 2017 issue of the journal Clinical Chemistry.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.